rtmark
LearnBonds.com

Inovio Stock Gains 12% on FDA Approval of Clinical Trials for New Coronavirus Vaccine

Inovio Pharmaceuticals (NASDAQ:INO) stock jumped more than 70% in the space of a week due to the company’s involvement in the development of a potential vaccine for the novel coronavirus.

Inovio Stock Gains %...

Previously burdened by debt and a lack of profitability, the latest update from the Pennsylvania-based pharmaceutical firm turned around the downtrend of its stock. As Inovio moves forward with clinical trials, shares of the biotech company edged higher.

News of The Food and Drug Administration accepting Inovio’s application mean the company will proceed with phase 1 clinical trials for its coronavirus vaccine. This is the second company to receive approval for human-based trials after Johnson & Johnson, who earlier this month announced a 1$ billion government deal for research and manufacturing of its coronavirus vaccine. While J&J is not expected to begin tests on human subjects until September, Inovio’s study is set to test two doses of its vaccine, code-named INO-4800, in 40 healthy volunteers at the Kansas City research lab and the University of Pennsylvania in the coming days.

Investors reacted positively to this development, which may produce significant gains for them in the long-term. Data regarding the effectiveness and safety of Inovio’s vaccine will be available as early as this summer but in the meantime, Inovio’s shares are marked as a strong ‘buy’.

Amid the uncertain economic climate, Inovio’s coronavirus vaccine is a welcomed addition to the firm’s pipeline. While it is still too early to discuss pricing for the developed vaccine, for comparison sake Merck’s MMR/Varicella vaccine costs upwards of $200. If just a quarter of the 327 million people in the US were to use Inovio’s vaccine, that’s 81 million syringes at $200 each— an addressable market worth $16.2 billion in the US alone. However, the main focus lies on the necessity for containing the growing health crisis – one that billionaire philanthropists like Melinda Gates have stressed need to ‘remain affordable’.

The Bill and Melinda Gates Foundation donated 125$ million towards research into a coronavirus vaccine.

“We have to make sure that the vaccine is very low priced and that there’s a fund for buying it for everyone, whether you’re in a low, middle, or a high-income country,” Melinda Gatessaid. “And that’s doable.”

Trusted & Regulated Stock & CFD Brokers

What we like

  • 0% Fees on Stocks
  • 5000+ Stocks, ETFs and other Markets
  • Accepts Paypal Deposits

Min Deposit

$200

Charge per Trade

Zero Commission

Rating

64 traders signed up today

Visit Now

75% of investors lose money when trading CFDs.

Available Assets

  • Total Number of Stocks & Shares5000+
  • US Stocks
  • German Stocks
  • UK Stocks
  • European
  • ETF Stocks
  • IPO
  • Funds
  • Bonds
  • Options
  • Futures
  • CFDs
  • Crypto

Charge per Trade

  • FTSE 100 Zero Commission
  • NASDAQ Zero Commission
  • DAX Zero Commission
  • Facebook Zero Commission
  • Alphabet Zero Commission
  • Tesla Zero Commission
  • Apple Zero Commission
  • Microsoft Zero Commission

Deposit Method

  • Wire Transfer
  • Credit Cards
  • Bank Account
  • Paypall
  • Skrill
  • Neteller

What we like

  • Sign up today and get $5 free
  • Fractals Available
  • Paypal Available

Min Deposit

$0

Charge per Trade

$1 to $9 PCM

Rating

Visit Now

Investing in financial markets carries risk, you have the potential to lose your total investment.

Available Assets

  • Total Number of Shares999
  • US Stocks
  • German Stocks
  • UK Stocks
  • European Stocks
  • EFTs
  • IPOs
  • Funds
  • Bonds
  • Options
  • Futures
  • CFDs
  • Crypto

Charge per Trade

  • FTSE 100 $1 - $9 per month
  • NASDAQ $1 - $9 per month
  • DAX $1 - $9 per month
  • Facebook $1 - $9 per month
  • Alphabet $1 - $9 per month
  • Telsa $1 - $9 per month
  • Apple $1 - $9 per month
  • Microsoft $1 - $9 per month

Deposit Method

  • Wire Transfer
  • Credit Cards
  • Bank Account
All trading carries risk. Views expressed are those of the writers only. Past performance is no guarantee of future results. The opinions expressed in this Site do not constitute investment advice and independent financial advice should be sought where appropriate. This website is free for you to use but we may receive commission from the companies we feature on this site.
Galina Mikova

Galina is a Hubspot-certified Technical Writer with over 10 years of experience in working with Fortune 500, private investment, banking, FOREX and niche tech companies as well as crypto and blockchain startups. She has a solid background in FinTech and blockchain technology.